FDAnews
www.fdanews.com/articles/75506-dendreon-signs-agreement-to-lease-manufacturing-facility-in-new-jersey

DENDREON SIGNS AGREEMENT TO LEASE MANUFACTURING FACILITY IN NEW JERSEY

August 18, 2005

Dendreon Corporation (Nasdaq: DNDN - News) today announced that it has signed an agreement to lease 158,242 square feet of commercial manufacturing space in Hanover, New Jersey. Dendreon intends to develop this facility to meet the anticipated clinical and commercial manufacturing needs for Provenge and its other active immunotherapy product candidates in development. Provenge is the Company's lead investigational active immunotherapy for the treatment of prostate cancer.

Yahoo News (http://biz.yahoo.com/prnews/050818/sfth037.html?.v=22)